Literature DB >> 23496866

Small molecule screen reveals regulation of survival motor neuron protein abundance by Ras proteins.

Reka R Letso1, Andras J Bauer, Mitchell R Lunn, Wan Seok Yang, Brent R Stockwell.   

Abstract

Small molecule modulators of protein activity have proven invaluable in the study of protein function and regulation. While inhibitors of protein activity are relatively common, small molecules that can increase protein abundance are rare. Small molecule protein upregulators with targeted activities would be of value in the study of the mechanisms underlying loss-of-function diseases. We developed a high-throughput screening approach to identify small molecule upregulators of the Survival of Motor Neuron protein (SMN), whose decreased levels cause the neurodegenerative disease spinal muscular atrophy (SMA). We screened 69,189 compounds for SMN upregulators and performed mechanistic studies on the most active compound, a bromobenzophenone analogue designated cuspin-1. Mechanistic studies of cuspin-1 revealed that increasing Ras signaling upregulates SMN protein abundance via an increase in translation rate. These findings suggest that controlled modulation of the Ras signaling pathway may benefit patients with SMA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23496866      PMCID: PMC3665055          DOI: 10.1021/cb300374h

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  39 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  E2A protein degradation by the ubiquitin-proteasome system is stage-dependent during muscle differentiation.

Authors:  L Sun; J S Trausch-Azar; A Ciechanover; A L Schwartz
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

Review 3.  The use of valproate and new antiepileptic drugs in status epilepticus.

Authors:  Eugen Trinka
Journal:  Epilepsia       Date:  2007       Impact factor: 5.864

4.  A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity.

Authors:  Sungchan Cho; Gideon Dreyfuss
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

Review 5.  Discovery and development of SAHA as an anticancer agent.

Authors:  P A Marks
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 6.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29

7.  A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing.

Authors:  L Pellizzoni; N Kataoka; B Charroux; G Dreyfuss
Journal:  Cell       Date:  1998-11-25       Impact factor: 41.582

Review 8.  Intracellular signaling pathways activated by neurotrophic factors.

Authors:  R A Segal; M E Greenberg
Journal:  Annu Rev Neurosci       Date:  1996       Impact factor: 12.449

Review 9.  Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.

Authors:  Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Cancer Control       Date:  2003 Sep-Oct       Impact factor: 3.302

10.  Mapping pathways and phenotypes by systematic gene overexpression.

Authors:  Richelle Sopko; Dongqing Huang; Nicolle Preston; Gordon Chua; Balázs Papp; Kimberly Kafadar; Mike Snyder; Stephen G Oliver; Martha Cyert; Timothy R Hughes; Charles Boone; Brenda Andrews
Journal:  Mol Cell       Date:  2006-02-03       Impact factor: 17.970

View more
  3 in total

Review 1.  Assays for the identification and prioritization of drug candidates for spinal muscular atrophy.

Authors:  Jonathan J Cherry; Dione T Kobayashi; Maureen M Lynes; Nikolai N Naryshkin; Francesco Danilo Tiziano; Phillip G Zaworski; Lee L Rubin; Jill Jarecki
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

Review 2.  Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment.

Authors:  Giovanna Menduti; Daniela Maria Rasà; Serena Stanga; Marina Boido
Journal:  Front Pharmacol       Date:  2020-11-12       Impact factor: 5.810

Review 3.  Compartmentalized Platforms for Neuro-Pharmacological Research.

Authors:  Amol D Jadhav; Li Wei; Peng Shi
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.